The following commentary and opinion is provided by Dr. Declan Fallon, an independent market researcher. If you have a particular interest in any of the stocks mentioned here please don't hesitate to contact Rocco and discuss whether they are suitable for your portfolio.
The stocks featured in this article were drawn from a screen employing the following fundamental criteria.
- Percentage Change in EPS from current Quarter to corresponding Quarter the previous year of 25% or more
- Percentage Change in EPS from Year-To-Date (YTD) to last YTD of 25% or more
- Percentage Change in Revenue from Year-To-Date (YTD) to last YTD of 25% or more
- Return on Average Equity of 17% or more
- Five year Revenue Growth Rate of 15% or more
- Market Captialization of $50m or greater
- Net Profit Margin of 18% or more.
- Recent close of $12 or higher
- Average 10-day trading volume of at least 250,000 shares.
- Apple (AAPL)
- Google (GOOG)
- Baidu.com (BIDU)
- VMware (VMW)
- Potash Saskatche (POT)
- Priceline (PCLN)
- Apache Corp (APA)
- Celgene Corporation (CELG)
With five of the eight stocks coming from the technology and software sector there is a healthy emphasis on this key bellwether sector, although both Apple and Google have received a sizable dose of pain in recent weeks. Of the two, Google looks better value as it quietly consolidates between $570-670 range. Apple was on course to double its share price over the course of 6 months before investors decided to grab profits. It will likely resolve as a consolidation, much like that of Google, but has yet to find where the low end of this consolidation range will be.
Baidu posted staggering gains from $10 to $165 in just over 2 years. The mini-Google (its $51bn Market Cap is a quarter of Google's $198 bn) has performed well over the last 6 months, but it might find it hard for a push past $165 given recent trading volume. Breaks of 52-week or multi-year highs require strong volume to consume the inevitable supply generated by doubting shareholders.
VMware has experienced a roller coaster 5-years. On its IPO launch it effectively jumped from $30 to $125 in the space of a few weeks, before a reality check sent it back to $17.25 during the nadir of the credit crisis. It has managed to crawl its way back to knock on the door of its IPO year high, doing so on much stronger buying second time around. The fundamentals are there, so the question is can the current price momentum be maintained?
Potash Corp. Saskatch saw tremendous price appreciation from 2006 to 2008; rallying from low $10s to $80 over this period. The credit crunch took its toll on the share price but it has managed to find repeated support at its 200-week moving average (a key long term trend measure). The stock currently trades at this moving average (although is below its 200-day moving average) which may be the call to attract buyers once more.
Priceline has been one of the years best performers and has posted incredible gains since the low of 2008. The stock is screaming for a stock split; daily volume of 450,000 shares at $725 is one which calls for a liquidity boost. Typically, stocks which split continue to perform well as they reflect a healthy stock, ergo a strong performing company.
Apache Corp, like Potash Corp, has kept itself under the radar since posting its high in 2008. The stock has effectively traded inside a $50 - $140 range since the high and doesn't look like changing that behavior anytime soon. The company was able to beat estimates on its last quarter and the estimates for Q1 2012 are 6% higher than for the same quarter last year. So while may be moving sideways, earnings are steadily climbing higher.
Celgene Corporation is the only pharmaceutical company inside the top-8 list. Of all the stocks on the list it's the one in the process of making a break out of a 4-year trading range. What's occurring now in Celgene is what one looks for from Potash and Apache Corp in the year ahead. Driving demand for stock has been incredible - if not relentless - earnings growth; the stock has gone from a reported $0.63 in Q1 2010 to an expected $1.13 for Q1 2012 - close to double its haul. It's no wonder buyers are liking it!
**** INFORMATION PROVIDED IN THIS ARTICLE IS NOT OFFERED AS RECOMMENDED INVESTMENT ADVICE. YOU SHOULD CONSULT A PROFESSIONAL FINANCIAL ADVISOR FOR ASSISTANCE MAKING INVESTMENT DECISIONS ****
**** DISCLOSURE: NO POSITIONS HELD BY DR. DECLAN FALLON ****
**** CONTACT: ROCCO AT (202) 321-5579 TO DISCUSS WHETHER THESE STOCKS ARE APPROPIATE FOR YOU ****


